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Allogeneic transfusions of red blood cell (RBC) concentrates have been related to an
increase in postoperative infections. Leukocytes present in RBC units might have
deleterious effects on the receptor immune system, provoking a state of immunosup-
pression that favors the development of postoperative infections (TRIM effect). The
bioactive substances released by leukocytes in a time-dependent form, accumulating in
blood components during storage, might be responsible for the TRIM effect. Multiple
observational studies with logistic regression have demonstrated a direct relationship
between transfusion and infection. However, several factors related to surgical difficulty
and patient illness severity might act as strong confounding variables on the relationship
studied. Randomized controlled trials designed to establish a causal relationship
between transfusion and infection have yielded contradictory results. While we await
new studies, allogeneic transfusions should be considered as a possible risk factor for
postoperative infection.
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In the past century, allogeneic blood transfusions
(ABTs) have been considered to constitute an
effective, relatively risk-free therapy. This belief
is based on the fact that current screening techni-
ques have considerably diminished transfusion
reactions and transmission of known viruses,
including hepatitis C, hepatitis B, human immu-
nodeficiency virus (HIV) and cytomegalovirus. In
the 1980s, Opelz et al. [1] reported that ABT of
cellular blood components improved renal allo-
graft survival in transplant patients. Years later,
the same group [2] published a cooperative study
on renal transplantation, including more than
16 000 patients, which showed a modest, but sig-
nificant, beneficial effect of ABT on survival of
transplanted kidneys. Since then, other favorable
effects of blood transfusion have been described,
such as reduced recurrence of Crohn’s disease in
surgically treated patients, and a decrease in the
frequency of spontaneous abortions in pregnant
women. In light of these findings, it seemed
obvious that ABT could have a positive therapeu-
tic effect, probably independent of the increase in
hemoglobin in the recipient.
Unfortunately, detrimental effects of ABT have
also been described. In 1981, Gantt [3] raised the
possibility that perioperative ABT was associated
with an increase in the recurrence rate for resected
malignancies, generally colorectal cancer. Shortly
thereafter, studies began which investigated
whether ABT could increase the risk of postopera-
tive infection in patients undergoing curative sur-
gery for colorectal cancer and Crohn’s disease. In a
prospective study of 168 patients undergoing sur-
gery for colorectal cancer [4], the ABT and hema-
tocrit on admission were significantly related to
postoperative infection. Although blood transfu-
sions were associated with surgical blood loss and
duration of surgery, which could act as confound-
ing variables, neither of these factors was signifi-
cantly associated with postoperative infection,
suggesting an independent relationship between
transfusion and postoperative infection. Since
then, more than 150 studies have examined the
association of perioperative blood transfusion
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with postoperative bacterial infection [5]. Most of
these are observational cohort studies and have
compared transfused patients with non-trans-
fused patients. Using multivariate analysis with
logistic regression, multiple variables were con-
sidered for their potential to affect the transfusion–
infection relationship. Such variables included
age, sex, severity scoring, shock, length of surgery,
hematocrit on hospital admission, immune
response, operative blood loss, and TNM stage
of the tumor. The final result showed that ABT
remained an important risk factor for postopera-
tive infection. These deleterious effects have been
shown in patients with colorectal cancer, with
Crohn’s disease, with gastrointestinal cancer, after
cardiac surgery, with polytraumatic injury, and
after undergoing liver transplant [6]. Allogeneic
transfusion is a significant predictor of postopera-
tive infection, maintaining a dose–response rela-
tionship, even if only one unit of blood is
transfused. Compared with other variables, ABT
may be the only or the main risk factor for post-
operative infection [7].
Accumulated evidence shows that allogeneic
transfusions have a profound negative effect on
the immune system [5]. This negative effect
implies an increase in the recurrence of surgically
resected tumors and the frequency of postopera-
tive infections. This clinical syndrome, whose pro-
duction mechanisms and clinical consequences
need to be determined, is known in the literature
as allogeneic blood transfusion-associated immu-
nomodulation (the TRIM effect) [8]. The TRIM
effect may have important consequences. Mortal-
ity related to the TRIM effect may exceed that
caused by the combination of other transfusional
risks. The measures directed at decreasing the
deleterious consequences of the TRIM effect could
result in savings of $6–12 billion, while reducing
the number of postoperative infections [9].
The mechanism(s) of the TRIM effect(s) remain
elusive, and the specific constituent(s) of allo-
geneic blood responsible for it is still unclear.
Allogeneic plasma, allogeneic white blood cells
(WBCs) and substances that accumulate in blood
components during storage have been implicated
in the pathogenesis of TRIM [5]. However, both
animal and human data suggest that TRIM effects
are most likely mediated by transfused allogeneic
WBCs and/or the substances originating in WBC
granules and accumulating in blood components
during storage [8].
WBCs present in transfused blood play a pri-
mordial role. Some donor lymphocytes can pro-
liferate in the recipient and circulate in the host for
months or years. This probably represents a tol-
erance phenomenon. In an undetermined way,
this presence of chimera can favor the TRIM effect
and perioperative infections [10]. Allogeneic
WBCs and/or bioactive substances originating
in WBCs produce immunosuppression in trans-
fused patients [11]. Allogeneic blood induces the
Th2 cells of the recipient, which simultaneously
infraregulates the activities of Th1 cells [12]. ABT
diminishes the immune cellular functions of mono-
cytes, macrophages, T-cells and natural killer cells,
downregulating the antigen-presenting cell and
T-cell functions. The CD4/CD8 ratio and interleu-
kin-2 production also decline [13]. This impaired
cellular immune response is the principal mechan-
ism proposed to explain the high incidence of
postoperative infections, the recurrence of surgi-
cally resected tumors, and the prolonged survival
of renal transplants (TRIM effect). However, these
changes are not specific to allogeneic transfusions.
Other factors, such as hemorrhage and extent of
trauma, can lead to immunosuppression them-
selves [13]. In addition, other non-immune
mechanisms can be involved.
An association between ABT and perioperative
infection has been clearly established from multi-
ple observational studies [4,7,14]. Such an associa-
tion persists after statistically adjusting for the
effects of multiple confounding factors considered
by the authors. However, with an observational
design, researchers can only control the effects of
confounding factors that are known and can be
measured, and can therefore be introduced into a
multivariate analysis [5,6]. Unfortunately, this
type of study does not measure the effects of other
unknown variables that can affect the relationship
between transfusion and infection. Transfusion
can be a marker of other uncontrolled variables
that may actually be producing the infection. The
illness severity, risk factor of infection in specific
sites, and variables related to surgery, can act as
strong confounding factors in the relationship
between allogeneic transfusion and postoperative
infection. Even when considering these variables,
results are not homogeneous. Vamvakas and Blaj-
chaman [5] demonstrated that the TRIM effect
disappeared when the effect of the confounding
variables was considered. In contrast, our group
carried out a case–control study to establish the
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risk factors related to acquisition of nosocomial
pneumonia in 684 patients undergoing cardiac
surgery [15], and the multivariate analysis showed
that transfusion of four or more units of blood was
associated with the acquisition of nosocomial
pneumonia. This association was independent of
blood loss and scoring severity, suggesting that the
TRIM effect acts significantly in the acquisition of
nosocomial pneumonia.
In an attempt to establish a causal relationship,
various randomized controlled trials (RCTs) have
been carried out [16–22]. In all of the RCTs,
patients were divided into two groups, depending
on the types of blood component transfused. The
treatment group was transfused with allogeneic
blood. The control group received autologous
blood (from the same patient) [16,17] or blood
poor in WBCs (blood from donors and WBC
depleted by filtration) [18–22]. Investigators tried
to verify whether patients from the treatment
group suffered more deleterious effects than
patients from the control group, assuming that
the factors leading to the necessity of transfusion
were present and randomly distributed between
both groups. Seven RCTs compared the incidence
of postoperative infection between recipients of
standard allogeneic RBCs or whole blood (treat-
ment group) and recipients of autologous or WBC-
reduced allogeneic RBCs (control group). Most of
them have been performed in patients undergoing
surgery for colorectal cancer [16–21]; only one trial
has been performed in patients undergoing car-
diac surgery [22]. In two studies, the primary
outcome parameter was the cancer-related prog-
nosis [16,20], and the secondary parameter was
infection rate. In the remaining trials, postopera-
tive infection was the main parameter studied [17–
19,21,22]. The outcome of these RCTs was contra-
dictory, even considering the different study
designs: two studies [18,19] reported a significant
(P< 0.05) TRIM effect (infection rate was greater in
the treatment group than in the control group),
two studies reported a marginally significant
(P< 0.10) effect [17,22], and three studies did not
detect an effect [16,20,21]. Various aspects make
the results of the RCTs comparable with those of
the observational studies. The investigators report
a dose–response relationship between the number
of units transfused and the rate of postoperative
infection. Considering the subgroup of patients
transfused with >3 units of blood, there was a
clearly lower infection rate in the group of patients
receiving depleted-WBC blood (P¼ 0.004) [22].
Also, if the comparison is only between transfused
patients and non-transfused patients, the infection
rate appeared to be much higher in the first group.
Therefore, present studies do not allow us to
conclude that the TRIM effect has a true impact on
the development of postoperative infections.
Observational studies have almost uniformly
shown an increase in perioperative infection rates
in transfused patients. However, scoring severity
and risk factors of infection in specific sites and
variables related to surgery should be considered
as strongly confounding when a relation between
allogenic transfusions and postoperative infec-
tions is considered. The RCT studies, designed
to establish a cause–effect relationship between
transfusion and infection, show contradictory
results that are difficult to reconcile. Owing to
the high suspicion that WBCs are involved in
the TRIM effect and that universal WBC depletion
has been instigated in many countries, it is improb-
able that new RCTs will be carried out to evaluate
the influence of WBC depletion on postoperative
infections [5].
During storage, RBCs undergo corpuscular
changes, including depletion of 2,3-diphosphogly-
cerate (2,3-DPG) [23], a decrease in deformability
[24], and progressive depletion of nitric oxide [25].
The depletion of 2,3-DPG may result in a signifi-
cant leftward shift in the oxyhemoglobin curve
and may have adverse clinical effects on oxygen
delivery in patients whose balance is precarious
[23,26]. The transfusion of stored, rigid RBCs
depleted of 2,3-DPG and nitric oxide could
predispose recipients to visceral ischemia and,
therefore, infection. Moreover, various bioactive
substances are released from WBCs during storage
in a time-dependent manner. If all these effects
were clinically important, the transfusion of WBC-
depleted blood or fresh blood components could
decrease morbidity. In addition, non-WBC-
reduced cellular blood components stored for long
periods should be associated with larger immu-
nomodulatory effects than fresh blood compo-
nents. Some investigators have demonstrated a
direct relationship between transfusion of blood
with prolonged storage time and increase in post-
operative morbidity. Fransen et al. [27] showed a
perioperative increase in bactericidal permeability
increasing the levels of protein (BPI), a marker of
activation of polymorphonuclear WBCs, in trans-
fused patients undergoing cardiac surgery. BPI
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levels progressively increased with storage time,
and patients who received intraoperative transfu-
sions had a less favorable postoperative outcome.
Marik and Sibbald [28], in a study on septic
patients receiving mechanical ventilation, found
that patients receiving ‘old’ transfused blood
(>15 days) developed signs of splanchnic ische-
mia. Prolonged storage time can increase the rate
of multiorganic post-traumatic failure [29], hospi-
tal stay [30], mortality [31], and especially, the rate
of postoperative infection. A recent study has
found a strong association between storage time
of RBC concentrates and postoperative pneumonia
[32]. Therefore, accumulated evidence indicates
that prolonged RBC storage could contribute to
the TRIM effect. There have even been specific
groups created to study the clinical importance
of the age of blood (age of blood evaluation inves-
tigators—ABLE group). However, other studies
have not found a relationship between prolonged
storage and hospital stay, used as a surrogate
marker of the postoperative morbidity [26]. More
importantly, in the RCT of Van Watering et al. [22],
pre-storage WBC depletion did not show advan-
tages over post-storage WBC depletion, suggest-
ing that prolonged storage is not a risk factor for
infection. Unfortunately, it would not be ethical to
do an RTC to evaluate the influence of prolonged
storage on postoperative infections.
It is possible that other elements in blood could
be related to postoperative infection. Allogeneic
plasma and platelets have been implicated in the
TRIM effect [5]. Our group has recently studied the
influence of blood components on the acquisition
of severe perioperative infections in 800 patients
undergoing cardiac surgery [33]. RBC transfusion
was associated with the presence of nosocomial
pneumonia. This association was exclusive
between RBC and pneumonia, and was not found
with other blood components or other severe
infections.
The risks associated with blood transfusions
have led to a re-evaluation of clinical transfusion
practices during the past 15 years. Guidelines for
blood transfusion have been issued by several
organizations, and the criteria for transfusion are
becoming more and more restrictive. Although, in
the authors’ opinion, there is no clear evidence to
support the existence of the TRIM effects, blood
transfusions should be considered a risk factor for
postoperative infection [34] until new studies clar-
ify this topic. The use of WBC-depleted units and/
or fresh blood components could decrease the rate
of postoperative infection.
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